Tilarginine

Tilarginine Overview

Tilarginine is an organic Guanidino-modified amino acid derivative of L-arginine. Chemically, it belongs to the class of organic compounds known as arginine and derivatives within the amino acids, peptides, and analogues sub-class of carboxylic acids and derivatives. Structurally, it consists of an L-arginine backbone bearing a single methyl group (-CH3) at one of the guanidino nitrogens, possessing a molecular weight of 188.23 g/mol (and 248.28 g/mol as the acetate salt, tilarginine acetate).

What Is Tilarginine and How Does It Work?

Tilarginine acts primarily through competitive inhibition of nitric oxide synthase (NOS) enzymes to block L-arginine conversion into nitric oxide (NO), driving inhibition of soluble guanylate cyclase, reduction of cyclic GMP (cGMP), vascular smooth muscle contraction, and elevation of systemic/ocular vascular resistance.

Is Tilarginine FDA Approved?

Tilarginine (L-NMMA) has undergone extensive clinical trial evaluation (including the global Phase III TRIUMPH trial for cardiogenic shock), but it is not currently approved by the US FDA as a commercial prescription drug. Its current regulatory status is Investigational Status / Not Approved.

What Was/Is Tilarginine Used For?

• Clinical research and treatment of refractory cardiogenic shock complicating acute myocardial infarction (reversing severe hypotension).
• Investigational treatment of septic shock and cytokine-induced vascular collapse (such as interleukin-2 toxicity).
• Diagnostic assessment of vascular endothelial function and nitric oxide-dependent vasodilation in cardiovascular disease.
• Physiological research probe for mapping ocular, retinal, and choroidal blood flow autoregulation in diabetic retinopathy, macular edema, and glaucoma.
• Basic science investigation into insulin sensitivity, obesity, and regional tissue perfusion in Type 2 Diabetes Mellitus.

Before Taking Tilarginine: Contraindications & Precautions

Do not administer Tilarginine to patients with a known severe hypersensitivity to tilarginine, L-arginine analogues, or formulation excipients. It is strictly contraindicated in patients with severe underlying coronary artery vasospasm, acute severe left ventricular failure without cardiogenic shock, or severe peripheral vascular insufficiency, as unbuffered NOS inhibition causes intense vasoconstriction that can precipitate myocardial ischemia or systemic hypoperfusion.

Who Should Not Take Tilarginine?

• Individuals with known severe hypersensitivity or allergy to Tilarginine or arginine derivatives.
• Patients with severe, fixed coronary artery disease prone to vasospastic (Prinzmetal) angina.
• Patients with severe primary pulmonary hypertension (NOS blockade worsens pulmonary vasoconstriction).

Tilarginine, Pregnancy & Safety

Nitric oxide plays a crucial physiological role in maintaining low uteroplacental vascular resistance and gestational blood pressure regulation. Systemic administration of NOS inhibitors like Tilarginine during pregnancy induces severe maternal hypertension, decreased uteroplacental blood flow, embryofetal growth restriction, and fetal demise in animal models. Controlled clinical trials in pregnant women have not been conducted. Tilarginine is strictly contraindicated during pregnancy unless required in life-threatening maternal critical care research settings. It is unknown whether Tilarginine is excreted into human breast milk; nursing should be avoided during investigational protocols.

Tell Your Doctor Before Taking Tilarginine

Inform your principal investigator or critical care physician if you have a history of severe heart failure, coronary artery disease, asthma, pulmonary hypertension, kidney disease, or diabetes.

Tilarginine Dosage & Administration

Formulated as a sterile, pyrogen-free solution for intravenous infusion (1 mg/kg to 5 mg/kg tilarginine acetate) or localized intra-arterial/ophthalmic diagnostic administration.

Tilarginine dosing is strictly protocol-driven within clinical research environments.

Standard Tilarginine Dosing

• Investigational Intravenous Cardiogenic Shock Dosing (Adults): Administered as a loading bolus of 1.0 mg/kg IV over 10 minutes, followed by a continuous IV infusion of 1.0 mg/kg/hour to 2.5 mg/kg/hour for 5 to 24 hours, titrated to mean arterial pressure (MAP >= 65 mmHg).
• Diagnostic Endothelial Function & Ocular Blood Flow Dosing: Administered via localized intra-arterial or topical/ocular application at microgram doses (10 mcg to 100 mcg/min) under continuous blood flow monitoring.
• Maximum Infusion Ceiling: Clinical trials cap maximum systemic infusion doses at 5.0 mg/kg/hour to prevent severe cardiac output depression.

How Was/Is Tilarginine Administered

• Intravenous formulations must be infused through a dedicated central venous catheter using a volumetric infusion pump.
• Continuous hemodynamic monitoring (arterial line and pulmonary artery catheter) is required during systemic infusion.

Tilarginine Clinical Efficacy & Research

In critical care cardiology and vascular physiology research, Tilarginine is one of the most thoroughly investigated nitric oxide synthase inhibitors. Phase II clinical trials in patients with cardiogenic shock complicating myocardial infarction established that intravenous Tilarginine rapidly increased systemic vascular resistance by 25% to 40% and elevated mean arterial pressure by 10 to 20 mmHg, allowing weaning from vasopressor catecholamines. However, the pivotal international Phase III TRIUMPH trial (Tilarginine Acetate Injection in a Randomized International Study in Heart Failure Complicating Acute Myocardial Infarction) demonstrated that while Tilarginine successfully raised blood pressure, it did not produce a statistically significant reduction in 30-day all-cause mortality compared to placebo, leading to discontinued development for that specific indication.

Tilarginine Side Effects & Safety Profile

Tilarginine exhibits a narrow therapeutic window governed by its potent vasoconstrictive mechanism. Safety hazards stem primarily from excessive systemic vasoconstriction and cardiac output suppression.

Adverse effects correlate directly with infusion rate and systemic concentration.

Common Tilarginine Side Effects

• Cardiovascular: Systemic hypertension, bradycardia (reflex vagal response to elevated blood pressure), and increased central venous pressure.
• Neurological & Gastrointestinal: Headache, nausea, and localized numbness.

Serious Tilarginine Adverse Events

• Depression of Cardiac Output: Excessive systemic vasoconstriction increasing left ventricular afterload, leading to a secondary decrease in cardiac index (CI) and stroke volume.
• Pulmonary Hypertension: Increased pulmonary vascular resistance (PVR) triggering right ventricular strain.
• Myocardial or Tissue Ischemia: Intense arteriolar constriction reducing microvascular perfusion to coronary, renal, or mesenteric vascular beds.

Managing Tilarginine Side Effects

If excessive hypertension, severe bradycardia, or falling cardiac output occurs during IV infusion, reduce or discontinue the Tilarginine infusion immediately; because Tilarginine is a competitive inhibitor, its effects reverse rapidly upon cessation, or can be counteracted by administering exogenous L-arginine or organic nitrates (glyceryl trinitrate).

Tilarginine Drug Interactions & What to Avoid

Tilarginine displays potent pharmacodynamic interactions with nitric oxide donors, vasopressors, and antihypertensive drugs.

Co-administration with specific drug classes directly antagonizes or amplifies its vasoconstrictive action.

Tilarginine Drug-Drug Interactions

• Nitric Oxide Donors (Nitroglycerin, Nitroprusside, Isosorbide Mononitrate): Directly supply exogenous NO, bypassing NOS inhibition and completely abolishing Tilarginine’s vasoconstrictive effect.
• L-Arginine: Exogenous L-arginine acts as a direct competitive substrate, displacing Tilarginine from the NOS active site and reversing enzyme inhibition.
• Catecholamine Vasopressors (Norepinephrine, Phenylephrine, Dopamine): Synergistic vasoconstriction; co-administration dramatically elevates systemic vascular resistance and blood pressure; lower doses of catecholamines are required.
• Phosphodiesterase-5 (PDE5) Inhibitors (Sildenafil, Tadalafil): PDE5 inhibitors prevent cGMP breakdown; co-administration blunts Tilarginine’s ability to lower cGMP levels.

Tilarginine, Food & Alcohol

Systemic food interactions do not occur with intravenous administration. High dietary intake of L-arginine-rich foods (nuts, seeds, red meat) can theoretically compete with oral/experimental uptake. Alcohol exacerbates central vasodilation, opposing Tilarginine’s vasoconstrictive effects.

Tilarginine: Missed Dose, Overdose & Storage

Proper handling of Tilarginine involves continuous intravenous monitoring in clinical research units. Overdose leads to severe hypertension and cardiac output suppression.

Adherence to proper storage parameters maintains amino acid stability and prevents oxidation.

Missed Dose of Tilarginine

Not applicable. Tilarginine is administered as a continuous intravenous infusion or controlled diagnostic application in clinical research settings.

Tilarginine Overdose & Emergency

Accidental massive overdose of Tilarginine causes severe systemic hypertension, marked reflex bradycardia, elevated pulmonary vascular resistance, reduced cardiac output, and tissue ischemia. Emergency management includes immediate cessation of the infusion, administration of intravenous L-arginine (to competitively displace Tilarginine from NOS enzymes), IV sodium nitroprusside or nitroglycerin (to directly restore NO levels), and supportive critical care monitoring.

How to Store Tilarginine

Store sterile investigational vials at controlled room temperature between 15°C and 25°C (59°F to 77°F) or refrigerated between 2°C and 8°C (36°F to 46°F) according to specific trial manufacturing guidelines. Protect strictly from light and freezing. Keep container tightly closed. Keep out of reach of children.

Tilarginine Patient Management & Monitoring

Clinical oversight for patients receiving Tilarginine focuses on continuous hemodynamic monitoring, evaluating cardiac output, and assessing tissue perfusion.

Regular clinical tracking ensures patient safety during investigational protocols.

Tests Before Starting Tilarginine

Baseline arterial blood pressure and heart rate; baseline hemodynamic monitoring (cardiac output, cardiac index, SVR, PCWP via pulmonary artery catheter or arterial line); baseline renal and liver function tests; baseline ECG.

Monitoring During Tilarginine Treatment

Continuous blood pressure and ECG monitoring; hourly cardiac output and systemic vascular resistance calculations during IV infusion; monitoring urine output and arterial blood gas (ABG) parameters; inspecting ocular microvascular blood flow during diagnostic eye protocols.

Tilarginine Do’s and Don’ts

• Do ensure continuous arterial line and cardiac monitoring are active during intravenous infusion.
• Do report chest pain, shortness of breath, or severe headache immediately during clinical trials.
• Do inform trial investigators of all medications you are taking, especially blood pressure pills or heart medicines.
• Do not attempt to adjust infusion pump rates independently.
• Do not take exogenous L-arginine supplements or nitric oxide boosters during trial protocols without investigator approval.

Frequently Asked Questions

References

• DrugBank Database – Tilarginine Clinical Profile (DB11815)
• Classyfire Database – Arginine and Derivatives / Carboxylic Acids Taxonomy Profile
• Journal of the American Medical Association (JAMA) – Effect of Tilarginine Acetate on Mortality in Patients With Cardiogenic Shock: The TRIUMPH Randomized Trial

Legal Disclaimer

The detailed medical and chemical information provided on this specific web page is intended strictly for educational and informational purposes regarding complex pharmacological mechanisms. It absolutely does not constitute professional medical advice, medical diagnosis, or specific treatment recommendations. Always consult a licensed healthcare provider before making any personal decisions regarding complex medical conditions, medication adjustments, or dietary changes.